WeChat Mini Program
Old Version Features

Lorlatinib with or Without Chemotherapy in ALK-driven Refractory/relapsed Neuroblastoma: Phase 1 Trial Results

Kelly C. Goldsmith,Julie R. Park,Kimberly Kayser,Jemily Malvar,Yueh-Yun Chi,Susan G. Groshen,Judith G. Villablanca,Kateryna Krytska,Lillian M. Lai,Patricia T. Acharya,Fariba Goodarzian,Bruce Pawel,Hiroyuki Shimada, Susan Ghazarian,Lisa States,Lynley Marshall,Louis Chesler,Meaghan Granger,Ami V. Desai,Rajen Mody,Daniel A. Morgenstern,Suzanne Shusterman,Margaret E. Macy,Navin Pinto,Gudrun Schleiermacher,Kieuhoa Vo,Holger C. Thurm,Joseph Chen, Marlon Liyanage,Gerson Peltz,Katherine K. Matthay,Esther R. Berko,John M. Maris,Araz Marachelian,Yael P. Mossé

Nature Medicine（2023）

Cited 41|Views53
Key words
Drug development,Paediatric cancer,Biomedicine,general,Cancer Research,Metabolic Diseases,Infectious Diseases,Molecular Medicine,Neurosciences
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined